<i>Interleukin 28B</i> Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients
In various genome-wide correlation studies, interleukin <i>(IL)28B</i> gene polymorphism has been strongly correlated with both the therapeutic and spontaneous mediated clearance of hepatitis C virus (HCV). Therefore, this study aimed to evaluate the genotype and allele frequency distrib...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Tropical Medicine and Infectious Disease |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2414-6366/7/9/230 |
| _version_ | 1797481684287881216 |
|---|---|
| author | Seham Mahrous Zaki Hanan Samir Ahmed Monkez Motieh Yousif Eman Mohamed Awad |
| author_facet | Seham Mahrous Zaki Hanan Samir Ahmed Monkez Motieh Yousif Eman Mohamed Awad |
| author_sort | Seham Mahrous Zaki |
| collection | DOAJ |
| description | In various genome-wide correlation studies, interleukin <i>(IL)28B</i> gene polymorphism has been strongly correlated with both the therapeutic and spontaneous mediated clearance of hepatitis C virus (HCV). Therefore, this study aimed to evaluate the genotype and allele frequency distributions of <i>IL28B (rs12979860)</i> in patients with chronic hepatitis C and assess the <i>IL28B</i> polymorphisms as predictors of sustained virological response to SOF-based therapy for HCV in Egyptian patients. This retrospective case-control study was conducted on 54 chronic HCV patients who completed treatment with SOF/DCV ± RBV for 12 weeks and responded to treatment with SVR12 (the responder group) as a control group, and 54 chronic HCV patients who completed treatment with SOF/DCV ± RBV for 12 weeks and did not respond to treatment and failed to achieve SVR12 (the non-responder group) as a case group. The CC genotype frequency of <i>IL-28B (rs12979860)</i> was greater in the responder group (51.9%). In contrast, the TT genotype frequency was higher in the non-responder group (48.1%) (<i>p</i> < 0.001), and the T allele significantly increased the risk of non-responses by 3.13 fold. Therefore <i>IL-28B (rs12979860)</i> SNP could be used as a genetic predictor of sustained virological response to SOF+DCV ± RBV-based HCV treatment in Egyptian patients. |
| first_indexed | 2024-03-09T22:19:04Z |
| format | Article |
| id | doaj.art-4384d703b69c44d0b68b89edbde7a318 |
| institution | Directory Open Access Journal |
| issn | 2414-6366 |
| language | English |
| last_indexed | 2024-03-09T22:19:04Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Tropical Medicine and Infectious Disease |
| spelling | doaj.art-4384d703b69c44d0b68b89edbde7a3182023-11-23T19:18:05ZengMDPI AGTropical Medicine and Infectious Disease2414-63662022-09-017923010.3390/tropicalmed7090230<i>Interleukin 28B</i> Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus PatientsSeham Mahrous Zaki0Hanan Samir Ahmed1Monkez Motieh Yousif2Eman Mohamed Awad3Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig 44519, EgyptClinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig 44519, EgyptInternal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig 44519, EgyptClinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig 44519, EgyptIn various genome-wide correlation studies, interleukin <i>(IL)28B</i> gene polymorphism has been strongly correlated with both the therapeutic and spontaneous mediated clearance of hepatitis C virus (HCV). Therefore, this study aimed to evaluate the genotype and allele frequency distributions of <i>IL28B (rs12979860)</i> in patients with chronic hepatitis C and assess the <i>IL28B</i> polymorphisms as predictors of sustained virological response to SOF-based therapy for HCV in Egyptian patients. This retrospective case-control study was conducted on 54 chronic HCV patients who completed treatment with SOF/DCV ± RBV for 12 weeks and responded to treatment with SVR12 (the responder group) as a control group, and 54 chronic HCV patients who completed treatment with SOF/DCV ± RBV for 12 weeks and did not respond to treatment and failed to achieve SVR12 (the non-responder group) as a case group. The CC genotype frequency of <i>IL-28B (rs12979860)</i> was greater in the responder group (51.9%). In contrast, the TT genotype frequency was higher in the non-responder group (48.1%) (<i>p</i> < 0.001), and the T allele significantly increased the risk of non-responses by 3.13 fold. Therefore <i>IL-28B (rs12979860)</i> SNP could be used as a genetic predictor of sustained virological response to SOF+DCV ± RBV-based HCV treatment in Egyptian patients.https://www.mdpi.com/2414-6366/7/9/230direct-acting antiviralshepatitis C virussofosbuvirdaclatasvirribavirin<i>interleukin 28B</i> polymorphism |
| spellingShingle | Seham Mahrous Zaki Hanan Samir Ahmed Monkez Motieh Yousif Eman Mohamed Awad <i>Interleukin 28B</i> Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients Tropical Medicine and Infectious Disease direct-acting antivirals hepatitis C virus sofosbuvir daclatasvir ribavirin <i>interleukin 28B</i> polymorphism |
| title | <i>Interleukin 28B</i> Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients |
| title_full | <i>Interleukin 28B</i> Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients |
| title_fullStr | <i>Interleukin 28B</i> Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients |
| title_full_unstemmed | <i>Interleukin 28B</i> Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients |
| title_short | <i>Interleukin 28B</i> Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients |
| title_sort | i interleukin 28b i polymorphism as a predictor of sustained virological response to sofosbuvir based therapy for hepatitis c virus patients |
| topic | direct-acting antivirals hepatitis C virus sofosbuvir daclatasvir ribavirin <i>interleukin 28B</i> polymorphism |
| url | https://www.mdpi.com/2414-6366/7/9/230 |
| work_keys_str_mv | AT sehammahrouszaki iinterleukin28bipolymorphismasapredictorofsustainedvirologicalresponsetosofosbuvirbasedtherapyforhepatitiscviruspatients AT hanansamirahmed iinterleukin28bipolymorphismasapredictorofsustainedvirologicalresponsetosofosbuvirbasedtherapyforhepatitiscviruspatients AT monkezmotiehyousif iinterleukin28bipolymorphismasapredictorofsustainedvirologicalresponsetosofosbuvirbasedtherapyforhepatitiscviruspatients AT emanmohamedawad iinterleukin28bipolymorphismasapredictorofsustainedvirologicalresponsetosofosbuvirbasedtherapyforhepatitiscviruspatients |